On August 31, 2006, Kauffman, Goss Stryker; Li, Chao; Lippa, Blaise Scott; Morris, Joel; Pan, Gonghua published a patent.Safety of 4-Ethyl-piperazine-1-carbonyl chloride The title of the patent was Preparation of bicyclic heteroaromatic derivatives as anticancer agents. And the patent contained the following:
The title compounds I [X, Z, V and W = N or CR1 (R1 = H, halo, CN, etc.); R4 = H, alkyl, (CR11R12)t(aryl), (CR11R12)t(4-10 membered heterocyclyl); R5 = H, alkyl, or R4 and R5 are taken together to form an oxo moiety; R6 and R7 are taken together to form a 4-10 membered (bi)cyclic or hetero(bi)cyclic ring system; B represents a fused 5-6 membered aromatic ring containing 0-2 heteroatoms; with provisos], useful for treating abnormal cell growth in mammals (no specific data given), were prepared Thus, reacting 4-chloro-7H-pyrrolo[2,3-d]pyrimidine with tert-Bu 5-chloro-1,2-dihydro-1’H-spiro[indole-3,4′-piperidine]-1′-carboxylate followed by deprotection afforded II. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds I and to pharmaceutical compositions for treating such disorders which contain the compounds I. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Safety of 4-Ethyl-piperazine-1-carbonyl chloride
The Article related to bicyclic heteroaromatic pyrrolopyrimidine pyrazolopyrimidine spiroindolepiperidine preparation antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of 4-Ethyl-piperazine-1-carbonyl chloride
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics